These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 7869676)

  • 1. Proteinuria and hypertension.
    Ritz E; Nowicki M; Fliser D; Hörner D; Klimm HP
    Kidney Int Suppl; 1994 Nov; 47():S76-80. PubMed ID: 7869676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuminuria of hypertensive patients.
    Rambausek M; Fliser D; Ritz E
    Clin Nephrol; 1992; 38 Suppl 1():S40-5. PubMed ID: 1295707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Microalbuminuria, hypertension, and cardiovascular risk].
    Deferrari G; Pontremoli R
    Cardiologia; 1994 Dec; 39(12 Suppl 1):159-62. PubMed ID: 7634260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Züchner C; Venneklaas U; Schrandt G; Schnieders M; Rangoonwala B; Berger J; Dominiak P; Zidek W;
    J Hypertens; 2006 Mar; 24(3):541-8. PubMed ID: 16467658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of albuminuria in hypertensive patients.
    Ritz E; Fliser D
    Clin Investig; 1992; 70 Suppl 1():S114-9. PubMed ID: 1591503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microalbuminuria in essential hypertension.
    Crippa G
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S74-7. PubMed ID: 11986900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk.
    Segura J; Ruilope LM
    Fundam Clin Pharmacol; 2005 Aug; 19(4):429-37. PubMed ID: 16011729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].
    Schmieder RE; Schrader J; Zidek W; Tebbe U; Bramlage P; Paar WD; Böhm M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2665-71. PubMed ID: 17109277
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjects.
    Bigazzi R; Bianchi S; Batini V; Guzzo D; Campese VM
    Am J Hypertens; 2006 Apr; 19(4):426-31. PubMed ID: 16580581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria and hypertension.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Minerva Med; 2005 Aug; 96(4):261-75. PubMed ID: 16179893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease and global cardiovascular risk in essential hypertension.
    Segura J; Campo C; Ruilope LM
    Minerva Med; 2004 Oct; 95(5):375-83. PubMed ID: 15467513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Albuminuria and cardiovascular risk: basal results of the KORAL-CARDIO study].
    González-Juanatey JR; Alegría E; Zamorano JL; Bertomeu V; Velasco O; Parrondo I; Honorato J
    Nefrologia; 2006; 26(4):426-32. PubMed ID: 17058853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of long-term risks for living related kidney donors by 24-h blood pressure monitoring and testing for microalbuminuria.
    Eberhard OK; Kliem V; Offner G; Oldhafer K; Fangmann J; Pichlmay R; Koch KM; Brunkhorst R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):415-9. PubMed ID: 9361933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Microalbuminuria].
    Olsen MH; Ibsen H; Mogensen CE
    Ugeskr Laeger; 2009 Jun; 171(25):2097-100. PubMed ID: 19671389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of metabolic syndrome on hypertension-related target organ damage.
    Mulè G; Nardi E; Cottone S; Cusimano P; Volpe V; Piazza G; Mongiovì R; Mezzatesta G; Andronico G; Cerasola G
    J Intern Med; 2005 Jun; 257(6):503-13. PubMed ID: 15910554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mild renal insufficiency and microalbuminuria as emerging cardiovascular risk factors].
    Gorostidi M
    Nefrologia; 2004; 24 Suppl(6):47-61, 187-235. PubMed ID: 15696896
    [No Abstract]   [Full Text] [Related]  

  • 18. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity.
    Jung O; Bickel M; Ditting T; Rickerts V; Welk T; Helm EB; Staszewski S; Geiger H
    Nephrol Dial Transplant; 2004 Sep; 19(9):2250-8. PubMed ID: 15238630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global risk stratification in primary hypertension: the role of the kidney.
    Leoncini G; Ratto E; Viazzi F; Conti N; Falqui V; Parodi A; Tomolillo C; Deferrari G; Pontremoli R
    J Hypertens; 2008 Mar; 26(3):427-32. PubMed ID: 18300851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.